The significance of changes in serum CEA level as a surrogate marker for evaluating tumor response to chemotherapy in non-small cell lung cancer

Japanese Journal of Lung Cancer

Volumn 48, Issue 1, 2008, Pages 26-32

  Ishiguro, Futoshi ^a   Mori, Shoichi ^a   Katayama, Tatsuya ^a   Okuda, Katsuhiro ^a   Sakakura, Noriaki ^a   Fukui, Takayuki ^a   Hatooka, Shunzo ^a   Shinoda, Masayuki ^a   Mitsudomi, Tetsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Carcinoembryonic antigen (CEA); Evaluation of tumor response; Response evaluation criteria in solid tumors (RECIST)

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOCETAXEL; ETOPOSIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINDESINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER THERAPY; CELL VIABILITY; CONTROLLED STUDY; DISEASE MARKER; HUMAN; LUNG NON SMALL CELL CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR CELL; WORLD HEALTH ORGANIZATION;

EID: 42649143785     PISSN: 03869628     EISSN: None     Source Type: Journal    
DOI: 10.2482/haigan.48.26     Document Type: Article

References (16)

1. WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No 48. Geneva: WHO; 1979.
2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States. National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
3. Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y, et al. Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci. 2003;94:1015-1020.
4. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, et al. Mesuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol. 2003;33:533-537.
5. Mazumdar M, Smith A, Schwartz LH. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol. 2004;57:358-365.
6. Sawabata N, Ohta M, Takeda S, Hirano H, Okumura Y, Asada H, et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg. 2002;74:174-179.
7. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg. 2004;78:216-221.
8. Hsu WH, Huang CS, Hsu HS, Huang WJ, Lee HC, Huang BS, et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg. 2007;83:419-424.
9. Japanese source
10. Japanese source
11. Salgia R, Harpole D, Herndon JE 2nd, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res. 2001;21:1241-1246.
12. Japanese source
13. Konishi K, Kuriyama K, Chino S, Isohashi K, Murata M, Tsuda K, et al. CT evaluation of response to chemotherapy and/or radiotherapy in primary lung cancer: comparison of response evaluation criteria in solid tumors (RECIST) and the WHO criteria, and comparison of both methods with the histological evaluation. Nippon Igaku Hoshasen Gakkai Zasshi. 2004;64:41-45.
14. Japanese source
15. Japanese source
16. Grossi F, Belvedere O, Fasola G, Ceschia T, Meduri S, Sibau A, et al. Tumor measurements on computed tomographic images of non-small cell lung cancer were similar among cancer professionals from different specialties. J Clin Epidemiol. 2004;57:804-808.